美國(guó)OSI Pharmaceuticals www.osip.com
OSI Pharmaceuticals Inc.致力于通過(guò)發(fā)現(xiàn)、開(kāi)發(fā)和銷售高質(zhì)量、創(chuàng)新和差異化的靶向治療藥物，延長(zhǎng)癌癥和糖尿病、肥胖癥患者的生命并改善患者的生活質(zhì)量，實(shí)現(xiàn)“調(diào)整藥物和改善生活”的目的。
OSI Pharmaceuticals是領(lǐng)先的生物科技企業(yè)，主要研究、開(kāi)發(fā)和銷售高質(zhì)量藥品，延長(zhǎng)全球癌癥和糖尿病患者的生命或改善其生活質(zhì)量。

2010年日藥商Astellas 40億美元收購(gòu)美生物技術(shù)公司OSI 

armaceuticals is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.

We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and strive to turn pioneering science into breakthrough therapies for patients suffering from life-threatening diseases.

Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. We are leveraging our understanding of Epithelial-Mesenchymal Transition (EMT) to develop molecular targeted therapies (MTTS) and to become a leader in the science underpinning EMT in cancer.

Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity. Our diabetes/obesity group has an emerging diabetes and obesity clinical pipeline with several innovative drug candidates that have progressed into clinical development. We believe our emerging neuroendocrine control with body weight and glycemia platform can be used to pioneer personalized medicine approaches in diabetes and obesity.

OSI has a dedicated team of approximately 500 research and development, regulatory, sales, marketing, commercial, and business professionals. We are headquartered in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom.